Integra LifeSciences (NASDAQ:IART) Misses Q4 Revenue Estimates
Medical device company Integra LifeSciences (NASDAQ:IART) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 11.5% year on year to $442.6 million. Next quarter’s revenue guidance of $380 million underwhelmed, coming in 7.7% below analysts’ estimates. Its non-GAAP profit of $0.97 per share was 13.5% above analysts’ consensus estimates.